Elan Pharma International Limited

Eastman-kodak Company

Merck Sharp + Dohme Corp.

Sterling Winthrop Inc.

Klan Pharma International Ltd.

Elaine Liversidge

Gary G Liversidge

Pramod P Sarpotdar

Greta A Gottardy

H William Bosch

Wolfgang H Gunther

Gregory L McIntire

Scott Jenkins

Karen C Thompson

Linden Wei

Piotr H Karpinski

Suhas D Shelukar

James Cunningham

Barbara Van Orman

Kenneth E Kellar

Lawrence De Garavilla

William H Bosch

The present invention is directed to novel pharmaceutical compositions of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine. The pharmaceutical compositions of this invention useful in the treatment or prevention of disorders such as psychiatric disorders including depression and anxiety, inflammatory diseases and emesis.

Pharmaceutical composition of a tachykinin receptor antagonist

Described are injectable formulations of nanoparticulate olanzapine that produce a prolonged duration of action upon administration, and methods of making and using such formulations. The injectable formulations comprise nanoparticulate olanzapine.

Injectable nanoparticulate olanzapine formulations

The present invention is directed to nanoparticulate active agent compositions comprising at least one peptide as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions.

Nanoparticulate compositions having a peptide as a surface stabilizer

Disclosed are methods of intravenous administration of nanoparticulate drug formulations to a mammal to avoid adverse hemodynamic effects: by reducing the rate and concentration of the nanoparticles in the formulations; or by pre-treating the subject with histamine; or by pretreating the subject with a desensitizing amount of the nanoparticulate drug formulations.

Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions

Nanoparticulate compositions comprising an insoluble organic drug and at least one polyethylene glycol-derivatized lipid adsorbed on the surface of the drug are described. The polyethylene glycol-derivatized lipid can be a PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, PEG-vitamin E, or a mixture thereof The compositions have an effective average particle size of less than about 1 micron. The invention also describes methods of making and using such compositions.

Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions

The present invention is directed to methods for preventing crystal growth and particle aggregation in nanoparticulate compositions. The methods comprise reducing a nanoparticulate composition to an optimal effective average particle size. The resultant nanoparticulate compositions exhibit prolonged particle size stability and minimal crystal growth, even following exposure to elevated temperatures.

Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions

Dispersible particles consisting essentially of a crystalline anticancer agent having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 1000 nm. Anticancer compositions comprising the particles exhibit reduced toxicity and/or enhanced efficacy, and can be administered by IV bolus injection.

Surface modified anticancer nanoparticles

This invention is directed to a magnetic resonance imaging composition for imaging of an organ rich in mitochondria comprising particles of a substantially insoluble manganese compound. In a preferred embodiment, the organ rich in mitochondria is the liver. In a further preferred embodiment, the particles are substantially nonmagnetic. In another preferred embodiment, the particles have a particle size of less than about 10 microns. In a still further preferred embodiment, the insoluble manganese compound is a manganese salt. The manganese compound is preferably selected from the group consisting of manganese phosphate, manganese carbonate and manganese 8-hydroxy quinolate. In another preferred embodiment, the composition of the present invention further comprises a surfactant. The present invention is also directed to a method of diagnosis comprising administering to a mammal a contrast effective amount of particles of a substantially insoluble manganese compound suspended or dispersed in a physiologically tolerable carrier and generating an NMR image of said mammal.

Growing community of inventors

West Chester, PA, United States of America

Elaine Liversidge